Publications by authors named "Meng X He"

Renal cell carcinoma (RCC) is characterized by recurrent somatic mutations in epigenetic regulators, which stratify patients into clinically significant subgroups with distinct prognoses and treatment responses. However, the cell type-specific epigenetic landscape of RCC-broadly and in the context of these mutations-is incompletely understood. To investigate these open questions, we integrated single nucleus ATAC sequencing data from RCC tumors across four independent cohorts.

View Article and Find Full Text PDF

Elevated levels of cadmium (Cd) have the ability to impede plant development. Aldo-keto reductases (AKRs) have been demonstrated in a number of plant species to improve tolerance to a variety of abiotic stresses by scavenging cytotoxic aldehydes; however, only a few AKRs have been identified to improve Cd tolerance. The OsAKR1 gene was extracted and identified from rice here.

View Article and Find Full Text PDF
Article Synopsis
  • The study examines the clonal architecture and evolution of 845 prostate cancer tumors, finding that tumors from self-reported Black patients tend to have more linear and monoclonal structures, linked to higher rates of biochemical recurrence.
  • It challenges previous beliefs by associating polyclonal architectures with worse clinical outcomes.
  • The research also introduces a new method for analyzing mutational signatures, revealing additional cases of genetic deficiencies that could have clinical significance and suggest further avenues for research.
View Article and Find Full Text PDF
Article Synopsis
  • A program was launched to provide free genomic testing for patients with rare cancers worldwide, specifically targeting histiocytosis, germ cell tumors (GCT), and pediatric cancers.
  • Patients were recruited through social media and advocacy groups, and 333 were enrolled, with 288 providing tumor tissue for analysis, resulting in significant clinical benefits for patients receiving genomically guided therapy.
  • The study highlighted the rarity of actionable genomic alterations in ovarian GCTs and demonstrated that direct outreach can effectively build cohorts for studying rare cancers' genomic landscapes.
View Article and Find Full Text PDF

Molecular profiling studies have enabled discoveries for metastatic prostate cancer (MPC) but have predominantly occurred in academic medical institutions and involved non-representative patient populations. We established the Metastatic Prostate Cancer Project (MPCproject, mpcproject.org), a patient-partnered initiative to involve patients with MPC living anywhere in the US and Canada in molecular research.

View Article and Find Full Text PDF

Unlabelled: Wnt signaling driven by genomic alterations in genes including APC and CTNNB, which encodes β-catenin, have been implicated in prostate cancer development and progression to metastatic castration-resistant prostate cancer (mCRPC). However, nongenomic drivers and downstream effectors of Wnt signaling in prostate cancer and the therapeutic potential of targeting this pathway in prostate cancer have not been fully established. Here we analyzed Wnt/β-catenin signaling in prostate cancer and identified effectors distinct from those found in other tissues, including aryl hydrocarbon receptor and RUNX1, which are linked to stem cell maintenance, and ROR1, a noncanonical Wnt5a coreceptor.

View Article and Find Full Text PDF
Article Synopsis
  • Immune checkpoint inhibitors (ICIs) show limited effectiveness for treating hormone receptor-positive (HR+) breast cancer, as evidenced by final overall survival results from a trial involving 88 patients.
  • The study compared eribulin with pembrolizumab, revealing no significant improvement in overall survival rates, despite some tumors showing immune response correlations.
  • Key findings suggest that immune infiltration and antigen presentation are linked to positive responses, while tumor heterogeneity and estrogen signaling contribute to treatment resistance, indicating a need for further research and validation in clinical settings.
View Article and Find Full Text PDF
Article Synopsis
  • Researchers studied prostate cancer that is likely to come back after treatment and found it can be treated better with certain therapies before surgery.
  • * They looked at tumor samples from patients who responded well to the treatment and those who didn't, finding specific genetic changes in each group.
  • * Understanding these differences could help doctors figure out which patients might benefit the most from these therapies in the future.
View Article and Find Full Text PDF

Gene fusions frequently result from rearrangements in cancer genomes. In many instances, gene fusions play an important role in oncogenesis; in other instances, they are thought to be passenger events. Although regulatory element rearrangements and copy number alterations resulting from these structural variants are known to lead to transcriptional dysregulation across cancers, the extent to which these events result in functional dependencies with an impact on cancer cell survival is variable.

View Article and Find Full Text PDF

Immune checkpoint blockade (ICB) results in durable disease control in a subset of patients with advanced renal cell carcinoma (RCC), but mechanisms driving resistance are poorly understood. We characterize the single-cell transcriptomes of cancer and immune cells from metastatic RCC patients before or after ICB exposure. In responders, subsets of cytotoxic T cells express higher levels of co-inhibitory receptors and effector molecules.

View Article and Find Full Text PDF

Metastatic castration-resistant prostate cancer is typically lethal, exhibiting intrinsic or acquired resistance to second-generation androgen-targeting therapies and minimal response to immune checkpoint inhibitors. Cellular programs driving resistance in both cancer and immune cells remain poorly understood. We present single-cell transcriptomes from 14 patients with advanced prostate cancer, spanning all common metastatic sites.

View Article and Find Full Text PDF
Article Synopsis
  • Sarcomatoid and rhabdoid renal cell carcinoma (RCC) are aggressive tumors that have not been well-defined in terms of their molecular and clinical properties.
  • Emerging research shows that immune checkpoint inhibitors (ICI) may be particularly effective against these tumors, although the reasons for this are not fully understood.
  • The study identifies unique molecular characteristics of S/R RCC, such as specific mutations and increased immune activity, which contribute to their aggressive nature and responsiveness to ICI treatments.
View Article and Find Full Text PDF
Article Synopsis
  • Precursor states of Multiple Myeloma (MM) require detailed molecular analysis to improve risk assessment and treatment strategies for patients.
  • Single-cell RNA sequencing revealed early immune system changes, including increased NK cell abundance and altered chemokine receptor expression in precursor stages like MGUS and smoldering myeloma (SMM).
  • The study identified loss of specific T-cells and dysregulation of MHC class II in monocytes, both contributing to T cell suppression, offering insights for better immune-based patient stratification in MM progression.
View Article and Find Full Text PDF
Article Synopsis
  • - The study investigated the effectiveness of the WEE1 inhibitor adavosertib combined with cisplatin in treating metastatic triple-negative breast cancer (mTNBC) in patients with limited prior chemotherapy.
  • - Out of 34 patients, the objective response rate (ORR) was 26%, with a median progression-free survival of 4.9 months, but the treatment didn't meet the predefined success benchmark of an ORR greater than 30%.
  • - Some patients showed signs of clinical benefit, demonstrating immune gene expression and T-cell activity in their tumors, suggesting potential for further research despite high treatment-related side effects.
View Article and Find Full Text PDF
Article Synopsis
  • - We analyzed 1,048 melanoma samples and found significant differences in their genomic characteristics based on subtypes (BRAF, (N)RAS, NF1, triple wild-type (TWT)), identifying unique secondary driver genes and mutational processes for each subtype.
  • - Each melanoma subtype showed distinct patterns of dysregulated pathways and co-mutation patterns that influence their response to immune checkpoint therapies, like increased TGF-β signaling in BRAF melanomas and disrupted SWI/SNF complex in (N)RAS melanomas.
  • - The study also highlighted the TWT subtype's DNA-repair defects, offering new insights into potential therapeutic approaches based on genetic profiling for treating different melanoma patient groups.
View Article and Find Full Text PDF
Article Synopsis
  • An amendment to the original paper has been released.
  • The amendment contains updates or corrections to the original content.
  • You can find the link to access this amendment at the top of the paper.
View Article and Find Full Text PDF
Article Synopsis
  • Large-scale sequencing studies need effective visualization tools for genomic data linked to diverse patient traits, often using co-mutation plots.
  • CoMut is a newly developed Python package that allows for the creation of customizable comutation plots from various input data types, providing a solution where current tools fall short.
  • CoMut is open source, available on GitHub under the MIT License, and can be easily accessed via Google Colab for users who prefer a no-installation option.
View Article and Find Full Text PDF

The immune composition of the tumor microenvironment influences response and resistance to immunotherapies. While numerous studies have identified somatic correlates of immune infiltration, germline features that associate with immune infiltrates in cancers remain incompletely characterized. We analyze seven million autosomal germline variants in the TCGA cohort and test for association with established immune-related phenotypes that describe the tumor immune microenvironment.

View Article and Find Full Text PDF

Purpose: Heterogeneity in tumor mutational burden (TMB) quantification across sequencing platforms limits the application and further study of this potential biomarker of response to immune checkpoint inhibitors (ICI). We hypothesized that harmonization of TMB across platforms would enable integration of distinct clinical datasets to better characterize the association between TMB and ICI response.

Methods: Cohorts of NSCLC patients sequenced by one of three targeted panels or by whole exome sequencing (WES) were compared (total n=7297).

View Article and Find Full Text PDF
Article Synopsis
  • Immune-checkpoint blockade (ICB), specifically anti-PD1, has shown effectiveness in treating melanoma, but it's unclear what factors predict patient responses.
  • In this study involving 144 melanoma patients, researchers found that tumor mutational burden was influenced by melanoma subtype, while new genomic and transcriptomic features, particularly related to antigen presentation, were better predictors of response.
  • They also noted that previous treatment with anti-CTLA4 affected response predictors, and created models that combine clinical, genomic, and transcriptomic data to better predict which tumors might resist anti-PD1 therapy.
View Article and Find Full Text PDF
Article Synopsis
  • Researchers used computer modeling to find neoepitopes, which are new immune targets, coming from intron retention events in tumor RNA.
  • The study demonstrated through mass spectrometry that these retained intron neoepitopes are effectively processed and displayed on MHC I molecules in cancer cells.
  • The findings suggest that these RNA-derived neoepitopes could play a significant role in developing personalized cancer vaccines in the future.
View Article and Find Full Text PDF

systems that incorporate features of the tumor microenvironment and model the dynamic response to immune checkpoint blockade (ICB) may facilitate efforts in precision immuno-oncology and the development of effective combination therapies. Here, we demonstrate the ability to interrogate response to ICB using murine- and patient-derived organotypic tumor spheroids (MDOTS/PDOTS). MDOTS/PDOTS isolated from mouse and human tumors retain autologous lymphoid and myeloid cell populations and respond to ICB in short-term three-dimensional microfluidic culture.

View Article and Find Full Text PDF
Article Synopsis
  • Parental care is crucial for mammal survival, yet the evolution of this behavior is not well understood.
  • In a study on two mouse species, researchers found significant genetic differences in parental behavior, with specific genomic regions impacting these traits differently in males and females.
  • The neuropeptide vasopressin was identified as a key factor that inhibits nest building, revealing it plays a role in the variations of parental care among species.
View Article and Find Full Text PDF